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Abstract
Background: Hyaluronic acid (HA) serum levels correlate with the histological stages of liver fibrosis in hepatitis C
virus (HCV) monoinfected patients, and HA alone has shown very good diagnostic accuracy as a non-invasive
assessment of fibrosis and cirrhosis. The aim of this study was to evaluate serum HA levels as a simple non-invasive
diagnostic test to predict hepatic fibrosis in HIV/HCV-coinfected patients and to compare its diagnostic
performance with other previously published simple non-invasive indexes consisting of routine parameters (HGM-1,
HGM-2, Forns, APRI, and FIB-4).
Methods: We carried out a cross-sectional study on 201 patients who all underwent liver biopsies and had not
previously received interferon therapy. Liver fibrosis was determined via METAVIR score. The diagnostic accuracy of
HA was assessed by area under the receiver operating characteristic curves (AUROCs).
Results: The distribution of liver fibrosis in our cohort was 58.2% with significant fibrosis (F≥2), 31.8% with
advanced fibrosis (F≥3), and 11.4% with cirrhosis (F4). Values for the AUROC of HA levels corresponding to
significant fibrosis (F≥2), advanced fibrosis (F≥3) and cirrhosis (F4) were 0.676, 0.772, and 0.863, respectively. The
AUROC values for HA were similar to those for HGM-1, HGM-2, FIB-4, APRI, and Forns indexes. The best diagnostic
accuracy of HA was found for the diagnosis of cirrhosis (F4): the value of HA at the low cut-off (1182 ng/mL)
excluded cirrhosis (F4) with a negative predictive value of 99% and at the high cut-off (2400 ng/mL) confirmed
cirrhosis (F4) with a positive predictive value of 55%. By utilizing these low and high cut-off points for cirrhosis,
biopsies could have theoretically been avoided in 52.2% (111/201) of the patients.
Conclusions: The diagnostic accuracy of serum HA levels increases gradually with the hepatic fibrosis stage.
However, HA is better than other simple non-invasive indexes using parameters easily available in routine clinical
practice only for the diagnosing of cirrhosis.
Background
Human immunodeficiency virus (HIV) infection influ-
ences the natural evolution of chronic hepatitis C
(CHC) infection by accelerating fibrosis progression and
increasing the rate of cirrhosis and end-stage liver dis-
ease in HIV/hepatitis C virus (HCV) coinfected patients
[1,2]. Despite a decline in morbidity/mortality from
opportunistic infections since the introduction of highly
active antiretroviral therapy (HAART), end-stage liver
disease continues to be a frequent cause of hospitaliza-
tion and death in patients coinfected with HIV and
HCV [3,4].
Staging liver fibrosis is considered to be an essential
part in the management of patients with CHC, because
it provides prognostic information and, in many cases,
assists in therapeutic decisions. For many years, the
diagnosis and quantification of fibrosis have relied on
liver biopsies, a procedure with several drawbacks
(bleeding in the liver and around the site of the proce-
dure, pain around the biopsy area, infection, damage to
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invasive diagnostic methods for determining liver fibro-
sis that are being validated, such as blood markers and
imaging methods [6].
One of these blood markers is hyaluronic acid (HA),
an essential component of the extracellular matrix in
virtually every tissue of the body. In the liver, HA is
mostly synthesized by hepatic stellate cells and degraded
by sinusoidal endothelial cells [7]. HA serum levels have
been found to correlate with the histological stages of
liver fibrosis in HCV monoinfected patients [8], and HA
alone has shown very good diagnostic accuracy for the
non-invasive assessment of fibrosis and cirrhosis [9,10].
The purpose of our study was to evaluate serum HA
levels as a simple non-invasive diagnostic test to predict
hepatic fibrosis in HIV/HCV-coinfected patients and to
compare its diagnostic performance with other pre-
viously published simple non-invasive indexes consisting
of routine parameters.
Methods
Patients
We carried out a retrospective cross-sectional study of
all patients with documented HIV/HCV coinfection who
underwent a liver biopsy between May 2000 and May
2007 at the HIV outpatient clinic of the Hospital Gre-
gorio Marañón in Madrid (Spain).
Liver biopsies were performed on patients who were
potential candidates for interferon plus ribavirin therapy
and had no prior HCV therapy. The inclusion criteria
were: availability of a frozen serum sample collected on
the day of liver biopsy; no clinical evidence of hepatic
decompensation; detectable HCV RNA by polymerase
chain reaction; negative for hepatitis B surface antigen;
CD4+ lymphocyte count higher than 200 cells/μL; anti-
retroviral therapy or no need for antiretroviral therapy;
and absence of diabetes, active opportunistic infections,
or active drug or alcohol addiction.
From our cohort of 361 patients with liver biopsy
data, only 201 could be included because they had had a
serum sample collected and frozen. The group of
excluded patients had significant differences in the num-
bers of patients on antiretroviral therapy with NNRTI
(included (104/201 patients (51.7%)) vs. excluded (57/
160 patients (36.3%)), p < 0.05), advanced fibrosis diag-
nosis (included (41/201 patients (20.4%)) vs. excluded
(18/160 patients (11.3%)), p < 0.05), undetectable plasma
HIV viral load (included (156/201 patients (77.6%)) vs.
excluded (90/160 patients (56.3%)), p < 0.05), plasma
HCV RNA>850.000 copies/ml (included (125/201
patients (75.8%)) vs. excluded (95/160 patients (63.3%)),
p < 0.05), and plasma AST levels (included (57 IU/L) vs.
excluded (65.5 IU/L), p < 0.05).
All work was conducted in accordance with the
Declaration of Helsinki. All patients gave their written
informed consent for the liver biopsies, and the Institu-
tional Ethics Committee approved the study.
Clinical and Laboratory data
Immediately prior to the liver biopsy, a fasting blood
sample was taken from the patient to analyze complete
blood counts, liver panel, basic metabolic panel, coagu-
lation tests, HIV viral load, and CD4
+ counts. The dura-
tion of HCV infection for all patients with a history of
intravenous drug use was estimated from the first year
needles were shared, and the others patients were con-
sidered to have an “unknown” HCV infection duration.
Also, a serum sample was immediately frozen (-70°C)
and stored for further assays.
HIV and HCV infection were documented in all
patients by enzyme-linked immunosorbent assay
(ELISA) and polymerase chain reaction (PCR). The
HCV viral load was measured by PCR (Cobas Amplicor
HCV Monitor Test, Branchburg, NJ, USA). HCV geno-
type was determined by hybridization of biotin-labeled
PCR products to oligonucleotide probes bound to nitro-
cellulose membrane strips (INNO-LiPA HCV II, Innoge-
netics, Ghent, Belgium). HA was tested in serum
samples by a commercially available quantitative ELISA
(HA-ELISA; Echelon Biosciences Inc., Salt Lake City,
UT, USA). Concentrations were assayed in duplicate.
For purposes of comparison with HA, we evaluated 5
reported simple models consisting of routine parameters
to predict liver fibrosis: Forns [11], APRI [12], FIB-4
[13], HGM-1 and HGM-2 indexes [14] (Table 1).
Liver biopsy and histology
Liver biopsies were performed on an outpatient basis
following the recommendations of the Patient Care
Committee of the American Gastroenterological Asso-
ciation [15]. All liver biopsies were performed by the
same physicians (J.B. and P.M.) with a suction needle
( H I S T O - C U T1 6 G ,S t e r y l a bS r l .M i l a n o ,I t a l y ) .U l t r a -
sound was routinely used to determine the percutaneous
biopsy site. We did not systematically record the size of
liver biopsy specimens, however, during the study per-
iod, only 5 out of 297 biopsies yielded insufficient liver
tissue for pathological diagnosis.
The liver tissue sections were fixed in fomalin, embedded
in paraffin and stained by hematoxylin-eosin, Mason’s tri-
chrome, and Perls’ iron. The samples were evaluated by a
single pathologist (E.A.). Liver fibrosis was estimated pro-
spectively following the criteria established by the META-
VIR Cooperative Study Group [16]. Fibrosis was scored as
follows: F0, no fibrosis; F1, portal fibrosis; F2 periportal
fibrosis or rare portal-portal septa; F3, fibrous septa with
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ging fibrosis); and F4, definite cirrhosis. The researchers in
charge of evaluating the biopsies, interpreting the clinical
data, or calculating and analyzing the reference standard
had no prior knowledge of results.
Statistical analysis
Overall, results are presented as medians (25
th percen-
tile, 75
th percentile) for continuous variables and as fre-
quencies and percentages for categorical data.
Comparisons between HA levels and fibrosis stage were
analyzed using the Mann-Whitney U-test. All tests were
two-tailed with a p-value ≤ 0.05 considered to be signifi-
cant. Statistical analysis was performed using SPSS 16.0
software (SPSS INC, Chicago, IL, USA) and STATA 9.1
(College Station, TX, USA).
We evaluated the diagnostic performance of all
indexes using the receiver operating characteristic
(ROC) curve constructed to study the absence and pre-
sence of significant fibrosis (F≥2), advanced fibrosis
(F≥3), and cirrhosis (F4), and comparing the area under
these ROC curves (AUC-ROCs) [17,18] with a nonpara-
metric ROC analyses adjusted by Sidak’s method for the
effect of multiple comparisons.
For each fibrosis stage, we chose a low cut-off at 95%
sensitivity (Se) used to predict the absence of the disease
and a high cut-off at 95% specificity (Sp) used to predict
the presence of the disease. Additional analyses of cut-
offs that optimized both Se and Sp were also performed.
The “optimal” cut-off was defined as the maximum of
(Se + Sp). We calculated the Se, Sp, positive predictive
value (PPV) and negative predictive value (NPV) for
each cut-off point. We also calculated the diagnostic
odds ratio (DOR) which expresses the strength of the
association between test result and disease: it is the ratio
of the odds of a positive result in a person with the tar-
get condition compared to a person without the condi-
tion [19]. A DOR of 1 suggests the test providing no
diagnostic evidence. Moreover, we also calculated the
likelihood ratios (LR) which describe how many times a
person with the target condition is more likely to have a
particular test result than a person without that condi-
tion. LRs contribute to change the probability that a tar-
get condition is present after the test has been made.
Binary tests have two LRs, positive and negative (LR+,
LR-). A LR of 1 indicates no diagnostic value.
Finally, we calculated the percentage of patients in
whom the results of the HA could have avoided the
biopsy. For this purpose, we constructed three new 2 ×
2 contingency tables combining the two cut-off points
for comparing the results that were lower than the low
cut-off (discarding significant fibrosis) and the results
that were higher than the high cut-off point (for signifi-
cant fibrosis, for advanced fibrosis, and for cirrhosis,
respectively) with the corresponding biopsy results.
From each table, patients correctly classified (true posi-
tive (TP) + true negatives (TN)) by the test would not
have needed the biopsy procedure.
Results
Patients
General characteristics of the 201 HIV/HCV-coinfected
patients at the time of liver biopsy are shown in Table
2. Overall, 94.5% were on HAART: 23.4% with protease
inhibitor based therapy, 51.7% with non-nucleoside ana-
logue based therapy, 12.4% with 3 nucleoside analogue
based therapy, and 7.5% with other drugs. The distribu-
tion of liver fibrosis in our cohort was 58.2% with signif-
icant fibrosis (F≥2), 31.8% with advanced fibrosis (F≥3),
and 11.4% with cirrhosis (F4).
Table 1 Simple non-invasive models for liver fibrosis consisting of routine parameters
Index Mathematical formula Reference
Forns 7.811 - 3.131 * LN(Platelet count (10
9/L) + 0.781 * LN(GGT) + 3.467 * LN (Age)
-0.014*cholesterol
[11]
APRI
100
40
109
*(
(/ )
)
(/ )
AST IU L
L Platelet count
[12]
FIB-4
Age years AST IU L
Platelet count L ALT IU L
() * ( / )
(/ ) * ( / ) 109 [13]
HGM-1
1
1 1 971 0 012 109 0 026 0 0 + +− e AST (IU/L) (. . * ( /) . * . Platelet count L 3 33* ) glucose(mg/dL) [14]
HGM-2
1
1 6 175 0 010 4 8 0 010 109
+ −− + e ALP INR (. . ( /) .* . * ( / IU L Platelet count L LI U L ). * (/ ) ) −0 007 AST
[14]
Abreviations: LN, logarithm neperian; GGT, gamma glutamyl transpeptidase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international
normalized ratio; ALP, alkaline phosphatase.
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Page 3 of 9Table 2 Characteristics of the 201 HIV/HCV-coinfected patients, who underwent liver biopsies
Characteristic Values
No. HIV-1 patients * 201
Sex (male) * 152 (75.6)
Age (years)
† 39.4 (36.8; 43.3)
HIV acquired by IVDU * 180 (89.6)
Prior AIDS * 62 (30.8)
Years since HCV infection
†, ‡ 21.3 (17.7; 24.3)
High alcohol intake
*, § 28 (14)
Antiretroviral therapy
Non treated * 10 (5)
PI-based * 47 (23.4)
NNRTI-based * 104 (51.7)
3 NRTI-based * 25 (12.4)
Other * 15 (7.5)
Months on HAART (n = 190)
† 50.2 (34.9; 65.7)
Stage of liver fibrosis *
F0 16 (8)
F1 68 (33.8)
F2 53 (26.4)
F3 41 (20.4)
F4 23 (11.4)
Fibrosis progression index
† 0.08 (0.05; 0.15)
HIV markers
Nadir CD4+ T-cells
† 210 (103; 324)
Baseline CD4+ T-cells/μL
† 490 (373; 660)
HIV-RNA < 50 cp/mL * 156 (77.6)
Log10 VL copies/mL (n = 45) 3.23 (2.71; 3.98)
HCV markers *
HCV genotype
1o r4 153 (77.3)
3 45 (22.7)
HCV-RNA >850,000 cp/ml 125 (75.8)
Hematologic parameters
†
Platelet count (× 10
9/L) 177 (140; 221)
Fibrinogen (mg/dL) 259 (228; 305)
INR 1 (1; 1.02)
Biochemical parameters
†
ALP (IU/L) 124 (81; 196)
AST (IU/L) 57 (37.5; 85)
GGT (IU/L) 113 (58; 208)
ALT (IU/L) 77 (49; 117)
AST/ALT 0.75 (0.6; 0.97)
*Absolute number (percentage).
†Median (25
th percentile; 75
th percentile). ‡The duration of HCV infection for patients with a history of intravenous drug use
(IVDU) was calculated starting from the first year needles were shared. Duration of HCV infection was considered to be unknown for subjects infected through
sexual contact. §Patients were questioned in relation to alcohol consumption. The consumption of > 50 gr. of alcohol per day for ≥12 months was considered as
a high intake.
Abbreviations: HCV, Hepatitis C virus; HIV-1, Human immunodeficiency virus type 1; IVDU, intravenous drug users; HAART, highly active antiretroviral therapy;
NRTI, nucleoside analogue HIV reverse transcriptase inhibitor; NNRTI, non-nucleoside analogue HIV reverse transcriptase inhibitor; PI, protease inhibitor; HIV-RNA,
HIV plasma viral load; HCV-RNA, HCV plasma viral load; INR, international normalized ratio; ALP, alkaline phosphatase; AST, aspartate aminotransferase; GGT,
gamma glutamyl transpeptidase; ALT, alanine aminotransferase.
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HA levels increased significantly with the stage of hepa-
tic fibrosis (Figure 1A). The highest values of HA were
found in cirrhotic patients. The AUC-ROC values of the
HA for significant fibrosis (F≥2), advanced fibrosis (F≥3)
and cirrhosis (F4) were similar to those of the Forns,
APRI, FIB-4, HGM-1 and HGM-2 indexes (Figure 2B).
Evaluation of cut-off points
For significant fibrosis (F≥2), using a low cut-off of
430 ng/mL HA, 13 of 84 (15.5%) patients with F<2 were
correctly identified, and only 6 of 117 (5.1%) patients
with F≥2 were misclassified (61.0% PPV and 68.4%
N P V ) .W i t hah i g hc u t - o f fo f1 8 0 0n g / m L ,3 6o f
117 (30.8%) patients with F≥2 were correctly identified,
and only 4 of 84 (4.8%) of patients with F<2 were mis-
classified (90% PPV and 49.7% NPV) (Table 3). Consid-
ering these low and high cut-off points, biopsies could
have been avoided in 24.4% (49/201) of patients by
using HA instead. When we applied an optimal cut-off
of 1250 ng/mL, 128 patients were correctly identified
(67 patients were TP and 61 patients were TN), and 83
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Significant fibrosis (F 2)
95% Confidence Interval
Test   Area 
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Bound 
Higher
Bound 
HA 0.671  0.596  0.746 
HGM-1  0.781  0.715  0.847 
Forns  0.740  0.670  0.809 
APRI  0.765  0.698  0.832 
FIB-4  0.731  0.662  0.801 
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Advanced fibrosis (F 3)
95% Confidence Interval
Test   Area 
Lower
Bound 
Higher
Bound 
HA 0.769  0.699  0.840 
HGM-2  0.843  0.783  0.902 
Forns  0.754  0.680  0.829 
APRI  0.762  0.688  0.836 
FIB-4  0.749  0.671  0.827 
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Cirrhosis (F4)
95% Confidence Interval
Test   Area 
Lower
Bound 
Higher
Bound 
HA 0.859  0.787  0.930 
HGM-2  0.917  0.875  0.958 
Forns  0.815  0.734  0.895 
APRI  0.801  0.724  0.877 
FIB-4  0.816  0.727  0.905 
Figure 2 Area under the receiver operating characteristic (AUC-
ROCs) curves of HA, HGM-1, HGM-2, FIB-4, APRI and Forns
indexes for significant fibrosis (F≥2), advanced fibrosis (F≥3)
and cirrhosis (F4).
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Figure 1 Box plots illustrating the distribution of HA values
against METAVIR fibrosis score. Horizontal lines inside each box
represent the median, and the lower and upper borders of the box
encompass the interquartile range. The vertical lines from the ends
of each box encompass the extreme data points.
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Page 5 of 9patients were misclassified (23 patients were false posi-
tive (FP) and 50 patients were false negatives (FN))
(Table 3). The diagnostic accuracy estimates, the PPV,
NPV, LR-, LR+ and DOR, all of them were not good
enough.
For advanced fibrosis (F≥3), using a low cut-off of 687
ng/mL, 49 of 137 (35.8%) patients with F<3 were cor-
rectly identified, and only 3 of 64 (4.8%) patients with
F≥3 were misclassified (40.9% PPV and 94.2% NPV).
With a high cut-off of 2290 ng/mL, 18 of 64 (28.1%)
patients with F≥3 were correctly identified and only 7 of
137 (5.1%) patients with F<3 were misclassified (72%
PPV and 73.9% NPV) (Table 3). Considering these low
and high cut-off points, biopsies could have been
avoided in 33.3% (67/201) of patients by using HA
instead. When we applied an optimal cut-off of 1250
ng/mL, 141 patients were correctly identified (47
patients were TP and 94 patients were TN), and 60
patients were misclassified (43 patients were FP and 17
patients were FN) (Table 3). The NPV value almost
reached 85% but the PPV, LR-, LR+ and DOR were not
good enough.
For cirrhosis (F4), using a low cut-off of 1182 ng/
mL, 100 of 178 (56.2%) patients with F<4 were cor-
rectly identified, and only 1 of 23 (4.3%) patients with
F4 was misclassified (22.2% PPV and 99% NPV). With
a high cut-off of 2400 ng/mL, 11 of 23 (47.8%)
patients with F4 were correctly identified, and only 9
of 178 (5.1%) patients with F<4 were misclassified
(55% PPV and 93.4% NPV) (Table 3). Considering
these low and high cut-off points, biopsies could have
been avoided in 52.2% (111/201) of patients by using
HA instead. When we applied an optimal cut-off of
1320 ng/mL, 136 patients were correctly identified
(21 patients were TP and 115 patients were TN), and
65 patients were misclassified (63 patients were FP
and 2 patients were FN) (Table 3). Using HA to pre-
dict cirrhosis, the NPV, LR-, and DOR value had good
enough values.
Discussion
In this study, we found that serum HA levels were posi-
tively correlated with the stages of liver fibrosis. More-
over, the AUC-ROC increased with the stage of fibrosis
with the highest value found for cirrhosis. HA was mod-
erately accurate at the diagnosis of F≥2( A U C - R O Co f
0.676), while it seemed to be a very useful method for
the detection of cirrhosis (AUC-ROC of 0.863). Many
fibrosis experts would consider non-invasive tests for
fibrosis with an AUC-ROC value of 0.85-0.90 to be as
Table 3 Diagnostic accuracy of hyaluronic acid (HA) measurement for significant fibrosis (F≥2), advanced fibrosis (F≥3)
and cirrhosis (F4) in our cohort
Cut-off TP FP TN FN
(*) Se
(95% CI)
(*) Sp
(95% CI)
(*) PPV
(95% CI)
(*) NPV
(95% CI)
LR+
(95% CI)
LR-
(95% CI)
DOR
(95% CI)
Significant fibrosis (F≥ 2)
430 (ng/mL) 111 71 13 6 94.9
(90.4 - 99.3)
15.5
(7.1 - 23.8)
61.0
(53.6 - 68.7)
68.4
(44.9 - 91.9)
1.12
(1.01 - 1.24)
0.33
(0.14 - 0.78)
3.39
(1.23 - 9.32)
1250 (ng/mL) 67 23 61 50 57.3
(47.9 - 66.7)
72.6
(62.5 - 82.7)
74.4
(64.9 - 84.0)
55.0
(45.2 - 64.7)
2.09
(1.43 - 3.06)
0.59
(0.46 - 0.75)
3.55
(1.9 - 6.5)
1800 (ng/mL) 36 4 80 81 30.8
(21.9 - 39.6)
95.2
(90.1 - 100)
90.0
(79.5 -100)
49.7
(41.7 - 57.7)
6.46
(2.39 - 17.46)
0.73
(0.63 - 0.84)
8.89
(3.02 - 26.13)
Advanced fibrosis (F≥ 3)
687 (ng/mL) 61 88 49 3 95.3
(89.3 - 100)
35.8
(27.4 - 44.2)
40.9
(32.7 - 49.2)
94.2
(86.9 - 100)
1.48
(1.29 - 1.70)
0.13
(0.04 - 0.40)
11.32
(3.37 - 37.99)
1250 (ng/mL) 47 43 94 17 73.4
(61.8 - 85.0)
68.6
(60.5 - 76.7)
52.2
(41.3 - 63.1)
84.7
(77.5 - 91.8)
2.34
(1.75 - 3.12)
0.39
(0.25 - 0.6)
6.04
(3.1 - 11.7)
2290 (ng/mL) 18 7 130 46 28.1
(16.3 - 39.9)
94.9
(90.8 - 98.9)
72.0
(52.4 - 91.6)
73.9
(67.1 - 80.6)
5.50
(2.42 - 12.51)
0.76
(0.63 - 0.91)
7.27
(2.85 - 18.52)
Cirrhosis (F4)
1182 (ng/mL) 22 78 100 1 95.7
(85.1 - 100)
56.2
(48.6 - 63.7)
22.0
(13.4 - 30.6)
99.0
(96.6 - 100)
2.18
(1.81 - 2.63)
0.08
(0.01 - 0.53)
28.21
(3.72 - 213.86)
1320 (ng/mL) 21 63 115 2 91.3
(77.6 - 100)
64.6
(57.3 - 71.9)
25.0
(17.1 - 34.9)
98.3
(95.5 - 100)
2.58
(2.04 - 3.26)
0.13
(0.04 - 0.51)
19.17
(4.4 - 84.4)
2400 (ng/mL) 11 9 169 12 47.8
(25.2 - 70.4)
94.9
(91.4 - 98.4)
55.0
(30.7 - 79.3)
93.4
(89.5 - 97.3)
9.46
(4.40 - 20.36)
0.55
(0.36 - 0.82)
17.21
(5.98 - 49.57)
For each fibrosis stage, we chose a low cut-off at 95% sensitivity (Se) used to predict the absence of the disease and a high cut-off at 95% specificity (Sp) used
to predict the presence of the disease.
Abbreviations: TP, true positive cases (correct diagnosis); FP, false positive cases (over-diagnosis); TN, true negative cases (correct diagnosis); FN, false negative
cases (missed cases); Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; LR, likelihood ratio; DOR, diagnostic odds ratio;
(*): values as percentage (%).
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authors have argued that some non-invasive markers of
fibrosis might be even more accurate than biopsies and
that most of the significantly discordant results between
biopsies and non-invasive tests may be due to the
method of obtaining biopsies that does not demonstrate
the actual liver fibrosis state (sampling error when per-
forming the biopsies) [21].
HA has been described as a component of several
fibrosis indexes or as a single parameter for the non-
invasive assessment of fibrosis/cirrhosis in HIV/HCV-
coinfected patients [22-25].I nH I V / H C V - c o i n f e c t e d
patients, there are few published studies with HA alone,
and they are limited by their small sample sizes [25] or
were designed to only evaluate significant fibrosis [23].
The diagnostic performance of HA was similar to the
Forns, APRI, FIB-4, HGM-1 and HGM-2 indexes for
our HIV/HCV-coinfected patients. We also found that
the AUC-ROC of HA was similar to the AUC-ROC
v a l u e so fA P R I ,F I B - 4 ,a n dF o r n si n d e x e so b t a i n e db y
other authors in HIV/HCV-coinfected patients [26-30]
but lower than the AUC-ROC values of APRI, FIB-4,
and Forns found in several studies carried out on HCV-
monoinfected patients [11,12,31]. In summary, according
to this study the performance of HA is not better than
several biomarkers using parameters easily available in
routine clinical practice in HIV/HCV-coinfected
patients.
The clinical utility of HA in our study was low except
for cirrhosis as the AUC-ROC for cirrhosis was the only
one that was higher than 0.850. Also, the NPV was 99%,
which could be acceptable for excluding cirrhosis. How-
ever, the PPV was only 55%, which is unacceptable for
the diagnosis of cirrhosis; although this value can be
explained due to the low number of cirrhotic patients in
our cohort. Naturally, ruling out cirrhosis is of less
importance in the management of patients than con-
firming such a diagnosis. According to all the available
data, the practical interest of the isolated use of HA for
assessing liver fibrosis in HIV/HCV-coinfected patients
in clinical practice seems to be rather low.
The advantage of HA over the other simple non-inva-
sive indexes (APRI, FIB-4, HGM-1 and HGM-2) is that
these indexes could be affected by some factors asso-
ciated with HIV infection such as biochemical and hae-
matological abnormalities and antiretroviral therapy
[32-34], which can lead to an increase in transaminases
or cholesterol in the blood [32-34]. HAART has
increased the incidence of significant metabolic distur-
bances. These metabolic disturbances produce clinical
manifestations which have an impact on the future
health of the HIV-infected patient, including hyperlipi-
daemia, lipodystrophy, metabolic syndrome, cardiovas-
cular disease and type 2 diabetes [35,36]. Moreover,
hepatotoxicity is a serious complication in patients tak-
ing HAART and coinfection with HCV increases the
risk of liver toxicity while taking antiretroviral therapy
[32]. HCV coinfection is associated with a 2 to 10-fold
chance of developing elevated transaminase levels during
HAART [33]. The evidence of severe hepatic dysfunc-
tion (coagulopathy or elevation of ammonia levels) is
suggestive of severe toxicity and HAART should be dis-
continued. However, the simple indexes (APRI, FIB-4,
HGM-1 and HGM-2) are calculated in a relatively easy
way using parameters easily available in routine clinical
practice. Even though HA is a single molecule, its quan-
tification is not commonly measured in hospitals, it can-
not be obtained from normal clinical data, and it is
more expensive.
While HA has been shown to be accurate when used
in combination with other parameters in HIV/HCV-
coinfected patients (SHASTA index [24], HGM-3 [22]),
its effectiveness at assessing liver fibrosis as an isolated
marker is poorer. For instance, according to data pub-
lished by our group very recently [22], the AUROC of
HGM-3, a combination which includes HA, was 0.939
for F≥3, whereas the corresponding figure for HA alone
reported here was 0.772. However, others authors have
reported AUC-ROC values for Hepascore, Fibrometer
and SHASTA (three indexes which include HA), and
Fibrotest [30] similar to AUC-ROC values of HA in our
patients.
Moreover, we used a commercial HA-ELISA test
(Echelon Biosciences) different from the enzyme-linked
protein binding assay (Hyaluronic Acid Test Kit, Cor-
genix, Westminster, CO, USA) or the sandwich enzyme
binding assay kit (Pharmacia, Uppsala, Sweden) used by
others authors [23,25,37-41]. To the best of our knowl-
edge, this test has not previously been reported as a
fibrosis test. So, this paper is a validation study of the
HA-ELISA test (Echelon Biosciences) although the HA
levels in this study are quite different (about 10 times
l a r g e r )f r o mt h o s ep r e v i o u s ly reported in HCV or HIV/
HCV patients [23,25,38-41].
Aside from these laboratory biomarkers, liver fibrosis
is evaluated using transient elastography (FibroScan)
[42]. Our group reported an excellent diagnostic perfor-
mance of liver stiffness for fibrosis and cirrhosis in HIV/
HCV-coinfected patients [43], which was higher than
the diagnostic performance of HA shown here.
The diagnostic performance analysis in our cohort had
several limitations: a) the low number of patients; b) this
study was made on patients with well preserved immune
function and the extrapolation to individuals with more
marked immune suppression would require further
study; c) we did not directly compare HA with
SHASTA, Fibrotest, Hepascore or Fibrometer because
we did not have all the clinical routine variables needed
Resino et al. BMC Infectious Diseases 2010, 10:244
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undertaken, and as a result of the use of the HA-ELISA
test (Echelon Biosciences) the values of these combining
scores would be quite different from those previously
reported; d) we could not give exact information regard-
ing biopsy length or portal tracts, but we found that
only 1.68% of biopsies were defective for pathological
diagnosis, and these cases were excluded from this
study; e) only one pathologist read the biopsies and the
biopsies were not validated by someone else; f) the
uneven distribution of the stages of fibrosis in our
cohort with a high proportion of absent to mild fibrosis
and a low proportion of cirrhosis (11%). However, we
carried out an analysis using the DANA method, which
is used when the distribution of fibrosis stages are highly
asymmetric [44], and we did not find a significant
increase in AUC-ROC values (data not shown).
Conclusion
The diagnostic accuracy of serum HA levels increases
gradually with the hepatic fibrosis stage. However, HA
is better than other simple non-invasive indexes using
parameters easily available in routine clinical practice
only for the diagnosing of cirrhosis.
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